← Back
Iambic Therapeutics
IAM · listed on Nasdaq · worth $592.51 million
$14.28
−3.38% on Oct 29
One insider buy in the last year, $11.5 million in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.5M shares
5% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, one insider bought Iambic Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Evan Lockwood Rachlin
Bought $11.5M on Oct 16 — 718,750 shares at $16.00, held through a trust or family, 28% of what they now own.
No earlier purchases to measure
All reports
Every insider trade and SEC report we hold for Iambic Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 19BoughtEvan Lockwood RachlinOct 19 · Traded Oct 16 · Director+28%via a trust or family718,750 @ $16.00$11.5M